Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 190 Publications

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 M1zsfWN6fG:2b4jpZ{BCe3OjeR?= NXvGbIpJPTBizszN MVm0PEBp NUn0cVJXTE2VTx?= Mnv1T4ltdHNiY3XscJMh[nlibX;y[UB1cGGwIEm5KS=> NFXrNWMyODR7OU[0Ny=>
OVCA 429 NVnR[5IzTnWwY4Tpc44hSXO|YYm= M{\R[lMxOCCwTR?= NEnQZ|g1QCCq MWPEUXNQ NILaVYlFcXO{dYD0d{BqdnSjY4SgcZVtfGmlZXzseYxieiC2dX3vdkB{eGincn;p[JM> NHvoPG8yODl7OUe2Oi=>
RPMI8226 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVOxNFAhdk1? Mn;COFghcA>? M{fqemROW09? M2jFfWlEPTB;M{Cgcm0> MXmxNVMxPjR6OR?=
Dox40 Ml2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVv4dW5pOTByIH7N Mn;wOFghcA>? MVPEUXNQ M3z3OGlEPTB;NECgcm0> MVWxNVMxPjR6OR?=
MR20 NYTMR5NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHywWpQyODBibl2= NFLCOlU1QCCq NXzERpA6TE2VTx?= MXPJR|UxRTJyIH7N MoLKNVE{ODZ2OEm=
LR5 MlSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3JeIptOTByIH7N NVTwZ4M6PDhiaB?= MoLuSG1UVw>? MX\JR|UxRTJyIH7N NXntd2tMOTF|ME[0PFk>
U266 NXnmbmEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnTNVAxKG6P MUe0PEBp MmPrSG1UVw>? NXTBVJVXUUN3ME2zJI5O MUGxNVMxPjR6OR?=
IM-9 NHHlTJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{C2cFExOCCwTR?= NY\Q[ZRjPDhiaB?= NHzxUGZFVVOR NVnwdFNHUUN3ME22JI5O Mn72NVE{ODZ2OEm=
Hs Sultan M4rQcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn32NVAxKG6P M3jxUlQ5KGh? NILJ[HBFVVOR MVLJR|UxRTJyIH7N M1u5cVEyOzB4NEi5
PAM-LY2 MnHCSpVv[3Srb36gRZN{[Xl? MWKxNFAhdk1? MYWxNkBp MluySG1UVw>? MY\Jcohq[mm2czDOSk3PwkJiYXP0bZZifGmxbh?= NVvib5pvOTF|NUC5NVM>
PAM 212 MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XTS|ExOCCwTR?= MWG3NkBp NEfHTJJFVVOR MVrJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MXixNVM2ODlzMx?=
PAM-LY2 MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrzT4I3OTByIH7N M3;1cFczKGh? NITYNlBFVVOR NGfVUWJKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= MnXUNVE{PTB7MUO=
B4B8 NIe4NplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX[xNFAhdk1? NFzOWoY4OiCq MX3EUXNQ NETRd4FKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NFr5U2syOTN3MEmxNy=>
B7E3 M2rne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrtdYhrOTByIH7N MmTXO|IhcA>? NIPNRYVFVVOR MoSzTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MmnHNVE{PTB7MUO=
UM-SCC-9 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;0VFkyODBibl2= NXnobYpLPzJiaB?= MkLpSG1UVw>? MYPJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MlHTNVE{PTB7MUO=
UM-SCC-11B M2HqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVqxNFAhdk1? NUW0b|FrPzJiaB?= M{\0OmROW09? MnXyTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MXuxNVM2ODlzMx?=
H460 MkfVSpVv[3Srb36gRZN{[Xl? M3TBWlExKM7:TR?= NEn3RWYzPCCq NFnlSWJFVVOR MYDJcoR2[2W|IFLjcE0zKHCqb4PwbI9zgWyjdHnvckBidmRiY3zlZZZi\2ViY3;ydoVt[XSnZDD3bZRpKEd{LV2gdIhie2ViYYLy[ZN1 NHjVcYsyOjR7MkGxOy=>
U266 M1P4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnJOVAxKG6pL33s MV60PEBp NInUe25FVVOR MUjJcohq[mm2czDj[YxtKGe{b4f0bC=> MYmxNlY{OTZzOR?=
ARH77 NX;iW3ByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfhOGY2ODBibnevcYw> NH7ERm81QCCq M17JV2ROW09? MmHVTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NE\BUGoyOjZ|MU[xPS=>
WAD-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPZO2o2ODBibnevcYw> MXW0PEBp NIjFeYtFVVOR MWnJcohq[mm2czDj[YxtKGe{b4f0bC=> NGn6cGMyOjZ|MU[xPS=>
U266/LR7 MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfoVm02ODBibnevcYw> M1vafVQ5KGh? NXvWOplJTE2VTx?= NGOxRWFKdmirYnn0d{Bk\WyuIHfyc5d1cA>? M3;kSFEzPjNzNkG5
U266/dox4 NW\BXI16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\xOVAxKG6pL33s MlWxOFghcA>? M3r4UGROW09? MWLJcohq[mm2czDj[YxtKGe{b4f0bC=> MXyxNlY{OTZzOR?=
RPMI8226/LR5 NWe0[WpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XkN|UxOCCwZz;tcC=> NVrkZVV{PDhiaB?= M1v1NmROW09? Ml64TY5pcWKrdIOgZ4VtdCCpcn;3eIg> MmDnNVI3OzF4MUm=
H460 NHGzV45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2G0ZVExKM7:TR?= MX63NkBp MWDEUXNQ NF\ofpBKSzVyPUGwNEBvVQ>? NWHSZ4psOTJ4M{G2NlA>
H358 M1jGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:1NVAh|ryP NVPDOlB{PzJiaB?= NV\D[4NLTE2VTx?= M3zY[WlEPTB;N{Cgcm0> MUWxNlY{OTZ{MB?=
H322 M37xR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjpNVAh|ryP MoriO|IhcA>? NV30PYx5TE2VTx?= MWrJR|UxRTZ{MDDuUS=> M4XnPVEzPjNzNkKw
H460 NHvUVXZHfW6ldHnvckBCe3OjeR?= M{T5bFExOCCwTR?= NUfQcnVGOjRiaB?= NUC1dWNLTE2VTx?= NXn5doNQUW6mdXPld{BIOi2PLYDoZZNmKGG{cnXzeEBidmRidIXieYxqdiCjc4PlcYJtgS2maYPhd5NmdWKueR?= M{PMXlEzPjNzNkKw
LNCap-Pro5 NHnSXWFHfW6ldHnvckBCe3OjeR?= M2rnXFEh|ryP M4TrTVQhcA>? M1W1TmROW09? M{LLd3N1[WKrbHn6[ZMheDV| MnHxNVQ3OTJ3M{K=
T29 MnSyRZBweHSxc3nzJGF{e2G7 M{HF[lUxKG6P MoTJOFghcCB? MYLEUXNQ NH\4ZYNKdmS3Y3XzJINmdGxiYYDvdJRwe2m| M1TRW|E3Pzd6MUe5
T29Kt1 NH\tWWRCeG:ydH;zbZMhSXO|YYm= NX35empEPTBibl2= MlqzOFghcCB? Ml\wSG1UVw>? MUnJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MW[xOlc4QDF5OR?=
HCT116 MVzBdI9xfG:|aYOgRZN{[Xl? NF\FOpY2OCCwTR?= M3PVVlQ5KGhi NGjXSYxFVVOR MYDJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MonXNVY4PzhzN{m=
HKe-3 M3iyPGFxd3C2b4Ppd{BCe3OjeR?= MoXLOVAhdk1? MWq0PEBpKA>? NYTjNGdETE2VTx?= NGnqSIJKdmS3Y3XzJINmdGxiYYDvdJRwe2m| M2fJUVE3Pzd6MUe5
NB-1691 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33jUFEh|ryP NUPqToVFPzJiaB?= NILzZ|ZKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iNTW= MoDtNVc3QDl4OES=
CHLA-255 NYXHOo9mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfZTmpsOSEQvF2= Ml\RO|IhcA>? MXnJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOiV? MknqNVc3QDl4OES=
SK-N-AS NITIV5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPzfYVLOSEQvF2= NX\1eox4PzJiaB?= MmPmTY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDFyJR?= NV;Gc|VSOTd4OEm2PFQ>
NB-1691 NV;WXYtmTnWwY4Tpc44hSXO|YYm= MorDNVAhdk1? M2jsflI1KGh? M1vy[HNq\26rZnnjZY51dHlicnXkeYNmeyClZXzsd{BqdiC2aHWgS|AwTzFicHjhd4U> NGjIcG8yPzZ6OU[4OC=>
CHLA-255 M{SzcGZ2dmO2aX;uJGF{e2G7 NFLpeWwyOCCwTR?= NFHNZpQzPCCq NFewUoZOd2Snc4TsfUBz\WS3Y3XzJINmdGy|IHnuJJRp\SCJMD;HNUBxcGG|ZR?= M{XqXlE4Pjh7Nki0
RPMI 8226 MWLGeY5kfGmxbjDBd5NigQ>? M4nYUlIxKG6P NVHWUWFsQCCq M1rUR3Nq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 NGDIRpIyQTR|NkC1NC=>
MM.1S MYfGeY5kfGmxbjDBd5NigQ>? NVLDNZZYOjBibl2= NEHXS2I5KGh? M1f5U3Nq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 M1TyclE6PDN4MEWw
U266 NWDVPXlETnWwY4Tpc44hSXO|YYm= NFjKR|QzOCCwTR?= MVm4JIg> M2fiNHNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 NW\mOGd5OTl2M{[wOVA>
OPM1 M{j5eWZ2dmO2aX;uJGF{e2G7 MUmyNEBvVQ>? MoO3PEBp M{nWenNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 MV6xPVQ{PjB3MB?=
INA6 NYnqXmoxTnWwY4Tpc44hSXO|YYm= M1HnPVIxKG6P Ml;yPEBp MnnjV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> MWqxPVQ{PjB3MB?=
OPM2 NV76cYRDTnWwY4Tpc44hSXO|YYm= M1;4OVIxKG6P MVe4JIg> MmjFV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> MYGxPVQ{PjB3MB?=
RPMI 8226 MVnGeY5kfGmxbjDBd5NigQ>? NGLRNmMzOCCwTR?= Mn;EPEBp M4XC[mlv\HWlZYOgSG5CKHO7boTo[ZNqew>? NFHsTFgyQTR|NkC1NC=>
BaF/3 M2q5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVqxNFAhdk1? M4L3OFQ5KGh? Ml3aTWM2OD14LkKgcm0> NF3nd5ozODNyNU[5Ni=>
BaF/3-p210 MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDQNVAxKG6P MlTJOFghcA>? NH3mSHFKSzVyPUSuO{BvVQ>? MUmyNFMxPTZ7Mh?=
TCC-S NGDDRlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37HTFExOCCwTR?= NHe1doU1QCCq NWmyNZhCUUN3ME2yMlghdk1? NWTaNHZjOjB|MEW2PVI>
BaF/3 M3\zeWZ2dmO2aX;uJGF{e2G7 NWnI[5lrPiCwTR?= MlyxOFghcA>? MlzsTY5lfWOnczDhJIdz\WG2IFexJINmdGxvY4njcIUh[XK{ZYP0 MlPVNlA{ODV4OUK=
BaF/3-p210 MWfGeY5kfGmxbjDBd5NigQ>? MVS2JI5O NXrxZW0{PDhiaB?= MULJcoR2[2W|IHGgd4xq\2i2IFexJINmdGxvY4njcIUh[XK{ZYP0 NX3ab2kxOjB|MEW2PVI>
BaF/3-p210 M4\1e2Z2dmO2aX;uJGF{e2G7 M2TFSlYhdk1? MXyyOEBp NXO1XpdsWmWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKGGwZDD0bIUh[WO2aY\peJkhd2ZiUnK= NVr6SFJMOjB|MEW2PVI>
Raji MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVuxJO69VQ>? MWSyOEBp MorJVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi M1LuUFIyOTdyOUi4
LCL-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;hNUDPxE1? M364PVI1KGh? MmexVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MUiyNVE4ODl6OB?=
LCL-2 NF3j[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXjWVVNOSEQvF2= M1P3Z|I1KGh? NWTRTWk4WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NFXWeHozOTF5MEm4PC=>
BJAB NUXTfW1oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHGcnpCOSEQvF2= NYPvUmo2OjRiaB?= NWH1ZVJuWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MljsNlEyPzB7OEi=
SNT-13 M4\NU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIG2RXUyKM7:TR?= NWLMUVVNOjRiaB?= NEHLdIFT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NUC3RYFsOjFzN{C5PFg>
SNT-16 NYLPeHlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vNblEh|ryP NW\ONIxVOjRiaB?= Mn\TVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MmewNlEyPzB7OEi=
Jurkat NEPEeYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkO2NUDPxE1? Mof4NlQhcA>? M13FVnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NV;zcGRuOjFzN{C5PFg>
KAI-3 NES2dmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVixJO69VQ>? NXiwTpRpOjRiaB?= MkT3VoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MXOyNVE4ODl6OB?=
SNK-6 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlOwNUDPxE1? MYmyOEBp M3HDfHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= M{S3WVIyOTdyOUi4
KHYG-1 NYS4UFdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\LZVEh|ryP M4L1V|I1KGh? MYDS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MoPHNlEyPzB7OEi=
SNT-16 MmXqRZBweHSxc3nzJGF{e2G7 NIP3RmsyKM7:TR?= MVG2JIg> M4DLbGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M3LIPVIyOTdyOUi4
Jurkat NELMOW9CeG:ydH;zbZMhSXO|YYm= NHnkbokyKM7:TR?= NXnPd5RvPiCq MmDRTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MoXTNlEyPzB7OEi=
KAI-3 MVPBdI9xfG:|aYOgRZN{[Xl? NETqSW8yKM7:TR?= MnLQOkBp NGSwRWpKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NYLCVZo5OjFzN{C5PFg>
KHYG-1 MXTBdI9xfG:|aYOgRZN{[Xl? MV:xJO69VQ>? MWC2JIg> MWPJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NWLsZo1zOjFzN{C5PFg>
SNT-13 NHnoW5FCdnSrdnnyZYwhSXO|YYm= M4TZO|Eh|ryP MY[yOEBp MWLJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> Mnf4NlEyPzB7OEi=
SNT-16 NGfqb4lCdnSrdnnyZYwhSXO|YYm= NF\1eoEyKM7:TR?= NFuzN2wzPCCq NWPKb3E3UW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY MlzBNlEyPzB7OEi=
KAI-3 MWPBcpRqfmm{YXygRZN{[Xl? MXmxJO69VQ>? M3r5elI1KGh? NVfYeYlPUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY M3XV[FIyOTdyOUi4
SNK-6 M4DsPGFvfGm4aYLhcEBCe3OjeR?= Mkf0NUDPxE1? MV6yOEBp M2G4b2lv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? NYTnSVExOjFzN{C5PFg>
RAW 264.7 M3;V[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDydJYyODBibl2= MYm0PEBp NWH1NVBTWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MoDiNlI1OjdzNUS=
A375 Mli3RZBweHSxc3nzJGF{e2G7 MlfFNVAhdk1? M1X1RVI1KGh? MVLJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MXOyN|A4QTB6Mx?=
BLM Mo\kRZBweHSxc3nzJGF{e2G7 NHz1W2UyOCCwTR?= MWWyOEBp NXnye|J1UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MXmyN|A4QTB6Mx?=
A375 Ml7jRZV1d3CqYXf5JGF{e2G7 M4Hoe|ExKG6P NXO3[nJUOTJiaB?= MkPjTY5lfWOnczDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO= NEPGN3kzOzB5OUC4Ny=>
BLM Mm\1RZV1d3CqYXf5JGF{e2G7 NInOdVEyOCCwTR?= NWCzc5N5OTJiaB?= NV\1PIJjUW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM> MWqyN|A4QTB6Mx?=
H1299 NHXWco5CeG:ydH;zbZMhSXO|YYm= M37PVVgxKG6P MYKyOEBp MUTEUXNQ MWXT[Y5{cXSrenXzJG5US0yFIHPlcIx{KHSxIF3TR{1l\XKrdnXkJIlEQS2rbnT1Z4VlKGGyb4D0c5Nqew>? NWTadYVNOjV|MkO2PVM>
Hut-78 MoHJSpVv[3Srb36gRZN{[Xl? MVyxNFAhdk1? MWOyOEBp MUPEUXNQ MULEc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVExKGW6cILld5Nqd25? MX[yOVY5OTN|NR?=
H9 NVLRW20xTnWwY4Tpc44hSXO|YYm= MYixNFAhdk1? M4roVlI1KGh? M3jYRWROW09? MVHEc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVEyKGW6cILld5Nqd25? NXXhTXRrOjV4OEGzN|U>
HH NXfiWFBLTnWwY4Tpc44hSXO|YYm= MUKxNFAhdk1? NGTiOZUzPCCq NV6ySZhLTE2VTx?= Ml3Z[I94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOiCneIDy[ZN{cW:w NHrnWpQzPTZ6MUOzOS=>
Hut-78 NIXEd|hOcWe{YYTpc44hSXO|YYm= NF;TSIMyODBibl2= M2S0bFI1KGh? MYPEUXNQ M4focXJm\HWlZYOgZ4VtdCCvaXfyZZRqd25iYomgPFDjiJN7MDW= Mnu4NlU3QDF|M{W=
HH NF\UVIhOcWe{YYTpc44hSXO|YYm= NWjSXpg3OTByIH7N M4PpcVI1KGh? M4\BOmROW09? NHnrUJFT\WS3Y3XzJINmdGxibXnndoF1cW:wIHL5JFgx6oDVOUGl NISwc5kzPTZ6MUOzOS=>
U937 NWr5flFMTnWwY4Tpc44hSXO|YYm= MlHvNVAxKG6P NYfGPJZqPiCq MVHJcoR2[2W|IFnMMVgh\XiycnXzd4lwdiCrbjDMVHMue3SrbYXsZZRm\CCXOUO3JI1i[3KxcHjh[4V{ NGHoSlczPTd7MUS3Oy=>
human PBMC MYjGeY5kfGmxbjDBd5NigQ>? MXyxNFAhdk1? NGrE[44zPCCq M3m2Smlv\HWlZYOgTWwuQCC{ZXzlZZNm MYeyOVc6OTR5Nx?=
ES6 NFy2ZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37OXGlEPTB;MD6wNFIyKG6P NYfHc5FFW0GQR1XS
SK-UT-1 MkfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHrOndKSzVyPUCuNVY{KG6P MYfTRW5ITVJ?
SH-4 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\kTWlEPTB;MD6xO|Mhdk1? MWTTRW5ITVJ?
TE-9 MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fVS2lEPTB;MD6xPFIhdk1? NUPCemNrW0GQR1XS
A253 M2LzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;4[mlEPTB;MD6yNFghdk1? NHvZc29USU6JRWK=
no-10 MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv4TWM2OD1yLkKxJI5O NVzxVZpCW0GQR1XS
MMAC-SF MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3sdWFoUUN3ME2wMlIyPiCwTR?= MVPTRW5ITVJ?
A101D NV;0bGdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTzO4VKSzVyPUCuNlI2KG6P MmLHV2FPT0WU
NTERA-S-cl-D1 NH3t[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjGOJZKSzVyPUCuNlQ{KG6P NYruTpNjW0GQR1XS
8-MG-BA NGH2TnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LubWlEPTB;MD6yOUBvVQ>? NVO1TIRnW0GQR1XS
KNS-42 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHz2dllKSzVyPUCuNlU5KG6P M4K5RnNCVkeHUh?=
LXF-289 M{PZT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIn4WFRKSzVyPUCuNlY6KG6P NEDOblNUSU6JRWK=
OVCAR-4 NELWTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17vWWlEPTB;MD6yPFkhdk1? MonDV2FPT0WU
LOUCY M1vpUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1r5SWlEPTB;MD6yPVMhdk1? NFTKbHVUSU6JRWK=
BB65-RCC NFPR[pJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInRTJFKSzVyPUCuN|A1KG6P M4HEUXNCVkeHUh?=
D-542MG Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwM{K5JI5O NHnSb4RUSU6JRWK=
ONS-76 MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX3TWM2OD1yLkOzJI5O NEjyTWdUSU6JRWK=
BB30-HNC NWX1cIR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXP5bm1XUUN3ME2wMlM{PSCwTR?= M3PIcHNCVkeHUh?=
KS-1 NX:zcJVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwM{Sgcm0> NEjVOoZUSU6JRWK=
A388 NUTNTZVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnW3TWM2OD1yLkO1OkBvVQ>? NGjvUJBUSU6JRWK=
ES8 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrkTWM2OD1yLkSgcm0> NFLNNFhUSU6JRWK=
MZ2-MEL NILUb|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2C2[mlEPTB;MD60NFchdk1? Mn3JV2FPT0WU
HCC2998 NV7FXY5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEWzbWFKSzVyPUCuOFEzKG6P MUjTRW5ITVJ?
D-247MG MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXIWXNKSzVyPUCuOFE{KG6P M{PkPXNCVkeHUh?=
ACN NV36bIdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzROGVKSzVyPUCuOFE4KG6P NFfmTFRUSU6JRWK=
LB2518-MEL NXjyUZlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DCT2lEPTB;MD60NlUhdk1? MV7TRW5ITVJ?
ES1 NW[2d2RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3uyeGlEPTB;MD60N{BvVQ>? NEWzR4RUSU6JRWK=
HCE-T MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\sOHVKSzVyPUCuOFM6KG6P MnPuV2FPT0WU
OS-RC-2 NX;VR4trT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHCTWM2OD1yLkS0JI5O MV\TRW5ITVJ?
MFH-ino NH;hOItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoH1TWM2OD1yLkS0N{BvVQ>? MVPTRW5ITVJ?
OCUB-M M3n1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;VfGlEPTB;MD60OFchdk1? MXvTRW5ITVJ?
CP66-MEL MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXsTWM2OD1yLkS3N{BvVQ>? M{HP[nNCVkeHUh?=
LB771-HNC NHTtcW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7LeZNKSzVyPUCuOFc1KG6P NHf5WlZUSU6JRWK=
DSH1 MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwNEigcm0> NYWzNYJGW0GQR1XS
HUTU-80 NGLOTm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;LTWM2OD1yLkWzN{BvVQ>? M3S4SnNCVkeHUh?=
CESS NYfTUWs6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkWyTWM2OD1yLkWzPEBvVQ>? NWTPdIE5W0GQR1XS
NCI-H747 MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDJPXBKSzVyPUCuOVM6KG6P NX;HU3o1W0GQR1XS
HT-144 NELz[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwNUe2JI5O NELFR4FUSU6JRWK=
COLO-829 M4[zdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2j3SmlEPTB;MD62NVQhdk1? MWrTRW5ITVJ?
A4-Fuk NVPvV4VZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLMNZNKSzVyPUCuOlI{KG6P NY\MN|Z6W0GQR1XS
GI-ME-N NFfG[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHpTWM2OD1yLk[zOEBvVQ>? M1\pfXNCVkeHUh?=
LB831-BLC NYr1cldCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHSTW1PUUN3ME2wMlY1OSCwTR?= NUf2SoNHW0GQR1XS
HOP-62 NV3VNodCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LvWGlEPTB;MD62OFchdk1? MoizV2FPT0WU
BB49-HNC M3L5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPkUWFwUUN3ME2wMlY2OiCwTR?= NIHifmRUSU6JRWK=
D-336MG MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2WyW2lEPTB;MD62OVchdk1? Mn;uV2FPT0WU
TK10 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPXTWM2OD1yLk[3PUBvVQ>? NIDzNopUSU6JRWK=
Ramos-2G6-4C10 Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn5[JZKSzVyPUCuOlk{KG6P MmfKV2FPT0WU
LB373-MEL-D M{LWUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwNzDuUS=> M2nRSHNCVkeHUh?=
SF126 MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwN{CxJI5O NGjJOnRUSU6JRWK=
UACC-257 M1zEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\oS41KSzVyPUCuO|Ehdk1? NGrE[HlUSU6JRWK=
KINGS-1 Mlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwN{KyJI5O Mm\PV2FPT0WU
LS-513 NX;mb3l6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[yU5ZKSzVyPUCuO|M6KG6P NFLjT3VUSU6JRWK=
GI-1 NV[yPFdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml72TWM2OD1yLke2OEBvVQ>? M2L4PHNCVkeHUh?=
ES7 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjvTWM2OD1yLke2OkBvVQ>? M1PSTHNCVkeHUh?=
LB2241-RCC M4LCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DsfmlEPTB;MD64NFQhdk1? NWnyOHJ3W0GQR1XS
D-263MG NG[2NZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XifmlEPTB;MD64NFchdk1? MV\TRW5ITVJ?
SW684 M4nsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jwfGlEPTB;MD64NlEhdk1? NWjleHRMW0GQR1XS
ML-2 NVn2bIFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPBVllKSzVyPUCuPFIyKG6P NWjWfY5bW0GQR1XS
SK-LMS-1 NYTRVmd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwOEW0JI5O M4XvdHNCVkeHUh?=
TE-5 M4nNVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojtTWM2OD1yLki2OUBvVQ>? NGDwbpFUSU6JRWK=
QIMR-WIL NGfpXmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfHTJdxUUN3ME2wMlg5QSCwTR?= M2Hw[HNCVkeHUh?=
NCI-H1355 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHTV45KSzVyPUCuPFk2KG6P MU\TRW5ITVJ?
SNB75 NV[3cJlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHyTWM2OD1yLkmxNkBvVQ>? Mm\UV2FPT0WU
RXF393 MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHoTWM2OD1yLkmxOEBvVQ>? MXvTRW5ITVJ?
IST-MEL1 NFTmOmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r1SGlEPTB;MD65NVchdk1? MkC3V2FPT0WU
SF268 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrZOJZwUUN3ME2wMlkzOyCwTR?= MmnVV2FPT0WU
KALS-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULTfmdUUUN3ME2wMlkzPSCwTR?= NGHwd3RUSU6JRWK=
HC-1 NGTKNWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Hm[WlEPTB;MD65O|Uhdk1? NEfp[VBUSU6JRWK=
SW872 M4L3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{G4Z2lEPTB;MD65PVYhdk1? NHjKTGxUSU6JRWK=
PSN1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHuUWM2UUN3ME2xMlAyKG6P MmWyV2FPT0WU
TE-1 NH;JRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUSzNWZZUUN3ME2xMlA{KG6P M2DPfnNCVkeHUh?=
TE-10 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjBeoJWUUN3ME2xMlA{KG6P MYrTRW5ITVJ?
RKO M37RVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonOTWM2OD1zLkC2JI5O MUDTRW5ITVJ?
LC-2-ad MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXzO5pKSzVyPUGuNFghdk1? M3\zfHNCVkeHUh?=
SK-MM-2 NF2wU|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVi4SoFSUUN3ME2xMlA6KG6P Mkj3V2FPT0WU
VA-ES-BJ MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL1cIVtUUN3ME2xMlA6KG6P NF;oSlVUSU6JRWK=
MZ7-mel NUfWUVVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTFwMEmgcm0> MYXTRW5ITVJ?
D-392MG NU\iO3pbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHhTlJKSzVyPUGuNUBvVQ>? M4PvTHNCVkeHUh?=
CCRF-CEM MmPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTFwMUOgcm0> NHOzW3lUSU6JRWK=
EM-2 MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlu4TWM2OD1zLkG2JI5O NWrRNJRbW0GQR1XS
HAL-01 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nxemlEPTB;MT6xPEBvVQ>? NWrY[3JTW0GQR1XS
TE-8 M3TZRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\QWGJMUUN3ME2xMlE6KG6P M3rHOnNCVkeHUh?=
NCI-H1882 NYO5VnFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTFwMjDuUS=> MmrlV2FPT0WU
Daudi M1T5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TnUGlEPTB;MT6yNkBvVQ>? NX\5ZmNSW0GQR1XS
BL-41 Mof2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7OTWM2OD1zLkK1JI5O NFu2TGFUSU6JRWK=
SR NV[0V3lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmr5TWM2OD1zLkK1JI5O M1PYRnNCVkeHUh?=
KM12 M3HjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPWWGVKUUN3ME2xMlI4KG6P NF3DSXRUSU6JRWK=
K5 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTFwMkigcm0> NYPwXlY1W0GQR1XS
A3-KAW MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\VN2lEPTB;MT6yPEBvVQ>? MX3TRW5ITVJ?
CMK MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoSxTWM2OD1zLkK5JI5O MmTEV2FPT0WU
Calu-6 NIrwOVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fITmlEPTB;MT6yPUBvVQ>? Mnf4V2FPT0WU
IST-SL2 MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPhTWM2OD1zLkOxJI5O NInVS5hUSU6JRWK=
OPM-2 NEjPTFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWniZlJMUUN3ME2xMlM{KG6P NGL2ZmFUSU6JRWK=
DU-4475 MoXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rIc2lEPTB;MT6zOkBvVQ>? MUHTRW5ITVJ?
ECC12 NILNblVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFwM{egcm0> NF:xb5lUSU6JRWK=
L-540 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;kXYZKSzVyPUGuN|chdk1? NHq4eGxUSU6JRWK=
CAS-1 MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrrcoFKSzVyPUGuN|chdk1? NV2xeXplW0GQR1XS
PF-382 NVPDbFZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nuSmlEPTB;MT60O{BvVQ>? MXHTRW5ITVJ?
LS-411N M{nQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnoS3NxUUN3ME2xMlU{KG6P NHHMOFJUSU6JRWK=
NCI-H69 MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[2ZmlEPTB;MT61OEBvVQ>? NV\OUm9NW0GQR1XS
NB12 NFnDZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XITmlEPTB;MT61OkBvVQ>? MVzTRW5ITVJ?
HEL MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{m4S2lEPTB;MT62NUBvVQ>? MV\TRW5ITVJ?
GCIY MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTFwNkKgcm0> NFrRN4hUSU6JRWK=
EHEB M1O1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTzTWM2OD1zLk[3JI5O NIfFeGFUSU6JRWK=
TGBC1TKB M3XhfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7yTWM2OD1zLkexJI5O MoDBV2FPT0WU
KURAMOCHI MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILi[5lKSzVyPUGuO|Ihdk1? Ml\nV2FPT0WU
U-266 NYfhPYlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq1TWM2OD1zLke2JI5O NGfrWnRUSU6JRWK=
LC4-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\YVHlwUUN3ME2xMlc6KG6P NYm3UXZ6W0GQR1XS
NCI-H2126 NHvTSI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vzeWlEPTB;MT64JI5O MUXTRW5ITVJ?
NCI-H1092 NYnx[ZpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml2zTWM2OD1zLkigcm0> NXKxTGpsW0GQR1XS
GB-1 M{DFZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV65WYR2UUN3ME2xMlgyKG6P NWLXTWZXW0GQR1XS
MV-4-11 M{LiOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13wVGlEPTB;MT64NkBvVQ>? MlnhV2FPT0WU
Becker NE[xVotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTFwOEOgcm0> NUTmfI9yW0GQR1XS
MPP-89 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7vTWM2OD1zLki5JI5O NWTNZVVvW0GQR1XS
BE-13 NELOPY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\CdHVKSzVyPUGuPVMhdk1? NVSxW3JlW0GQR1XS
697 M2\LT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3UTZRKSzVyPUGuPVkhdk1? MYjTRW5ITVJ?
NKM-1 M4TINWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfWVmRKSzVyPUKgcm0> NFrR[JRUSU6JRWK=
NB13 NWTwVHpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;3XGlEPTB;MjDuUS=> NHraR3RUSU6JRWK=
LS-123 NIfDZo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fFZmlEPTB;Mj6wNkBvVQ>? NGezdJRUSU6JRWK=
NB17 Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\ubXc2UUN3ME2yMlA1KG6P NVLWdYRsW0GQR1XS
LAN-6 NXH6TZVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTJwMEWgcm0> M1m4e3NCVkeHUh?=
EW-24 MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHv4PGlKSzVyPUKuNFghdk1? M2PYTXNCVkeHUh?=
NOS-1 M2TPc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPRXHdKSzVyPUKuNVEhdk1? NEHPeFFUSU6JRWK=
BL-70 M3TYTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTJwMUKgcm0> MorWV2FPT0WU
GT3TKB MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIL0bGZKSzVyPUKuNVIhdk1? M4X4VXNCVkeHUh?=
HH M1LrOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTJwMUOgcm0> M3LXenNCVkeHUh?=
KE-37 NF\KU2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[1cmlEPTB;Mj6xN{BvVQ>? M3LSbXNCVkeHUh?=
MOLT-4 NFPBd2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPkOmFKSzVyPUKuNVMhdk1? NYHEfZQ3W0GQR1XS
EKVX NGn0WG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHVdlJXUUN3ME2yMlE1KG6P Ml\sV2FPT0WU
KGN NVrhO49bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HIbGlEPTB;Mj6xOUBvVQ>? NHrldZdUSU6JRWK=
ES4 M3iy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTJwMU[gcm0> MoLIV2FPT0WU
SJSA-1 NFrMb2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTJwMkGgcm0> M1L4SXNCVkeHUh?=
KMOE-2 NU\SR|JET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDofXBKSzVyPUKuNlMhdk1? M1LmenNCVkeHUh?=
NB5 MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LWOmlEPTB;Mj6yO{BvVQ>? NXfpbY1XW0GQR1XS
BC-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlK0TWM2OD1{LkOxJI5O NXe5SW8zW0GQR1XS
NB10 NELDcVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmWxTWM2OD1{LkOyJI5O NV\wUlJ4W0GQR1XS
RPMI-8226 MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DS[WlEPTB;Mj6zOUBvVQ>? MULTRW5ITVJ?
SCC-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXxXFBCUUN3ME2yMlM4KG6P NHL3[ZZUSU6JRWK=
ARH-77 M{HuOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjQeoZQUUN3ME2yMlM5KG6P NF6z[GxUSU6JRWK=
NCI-H748 NH7nRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jlW2lEPTB;Mj6zPUBvVQ>? M2Wy[HNCVkeHUh?=
KU812 MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLOeZVKSzVyPUKuOFIhdk1? MkPDV2FPT0WU
NCI-H64 MlrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrsbW5KSzVyPUKuOFQhdk1? Mmf2V2FPT0WU
NB69 MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV25PJdJUUN3ME2yMlQ3KG6P NGHEdmlUSU6JRWK=
KNS-81-FD NFL5WIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTJwNEigcm0> NHLHT41USU6JRWK=
LB1047-RCC NWXBWGVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJwNUegcm0> MXLTRW5ITVJ?
EB-3 NGnRTWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID5UYpKSzVyPUKuOlYhdk1? NWTab|lHW0GQR1XS
Mo-T MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTJwN{Sgcm0> M4\PRXNCVkeHUh?=
EW-16 NIHZNGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILzS2NKSzVyPUKuO|Uhdk1? NFjNVZpUSU6JRWK=
CTV-1 NEfmVY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TVN2lEPTB;Mj64JI5O NITwPFhUSU6JRWK=
ETK-1 NX7VOIdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f5XmlEPTB;Mj64OEBvVQ>? NYW4Z3JTW0GQR1XS
C2BBe1 NIX5XFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\kTWM2OD1{Lki5JI5O MW\TRW5ITVJ?
MOLT-16 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml65TWM2OD1{Lki5JI5O NIO3dHFUSU6JRWK=
SW954 MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTRbpUzUUN3ME2yMlkhdk1? MmizV2FPT0WU
HT M122[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHFTWM2OD1|LkCyJI5O MXXTRW5ITVJ?
KARPAS-299 NE\ldYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHxZ|lKSzVyPUOuNFYhdk1? NVu1b2s5W0GQR1XS
MONO-MAC-6 MkWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jHWWlEPTB;Mz6xJI5O NXKyO4dYW0GQR1XS
CGTH-W-1 NYDjOVJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnWUZNKSzVyPUOuNUBvVQ>? NW\MW3VTW0GQR1XS
SK-PN-DW MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljBTWM2OD1|LkG0JI5O MV;TRW5ITVJ?
CW-2 M2nKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PXV2lEPTB;Mz6yNUBvVQ>? M3vUOXNCVkeHUh?=
SK-N-DZ NF7pc3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jsN2lEPTB;Mz6yOkBvVQ>? M1XUZnNCVkeHUh?=
NEC8 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIj6c29KSzVyPUOuN|Uhdk1? MYHTRW5ITVJ?
LB996-RCC Mon0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXP6UY97UUN3ME2zMlQhdk1? NXPmd|ZXW0GQR1XS
DB NVT6OJJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{e0e2lEPTB;Mz60NUBvVQ>? MkHvV2FPT0WU
TE-15 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjldodvUUN3ME2zMlQ{KG6P Mm\jV2FPT0WU
COR-L88 NYK3Wnh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTIXo1rUUN3ME2zMlQ4KG6P NHv4bHZUSU6JRWK=
LAMA-84 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfTdo5KSzVyPUOuOFkhdk1? MlrMV2FPT0WU
MEG-01 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;0ZpZKSzVyPUOuOFkhdk1? MlrzV2FPT0WU
LOXIMVI MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3iTWM2OD1|LkWgcm0> NHrBRmRUSU6JRWK=
RPMI-8402 NILtWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKyR4JKSzVyPUOuOUBvVQ>? NHfaXFRUSU6JRWK=
KARPAS-45 NYnDdIo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjBTWM2OD1|LkW0JI5O M{PLTXNCVkeHUh?=
HCC1187 MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTNwNUSgcm0> NVH2b2t[W0GQR1XS
MZ1-PC M{f5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X6eGlEPTB;Mz61OEBvVQ>? NX3WOoRCW0GQR1XS
no-11 NHzvR|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLZTWM2OD1|LkW1JI5O NXvRbYZGW0GQR1XS
EVSA-T MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjlTWM2OD1|Lk[gcm0> Mn2wV2FPT0WU
DJM-1 NWPVVVBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HjdmlEPTB;Mz62N{BvVQ>? M{Pme3NCVkeHUh?=
COLO-684 NEiyRo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPyW|NKSzVyPUOuOlYhdk1? NVXxVo9iW0GQR1XS
NMC-G1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYG2XpZTUUN3ME2zMlY5KG6P MUHTRW5ITVJ?
LC-1F NHThc|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPXfYVQUUN3ME2zMlc1KG6P NXXOUZFDW0GQR1XS
RL95-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXQPGE1UUN3ME2zMlc6KG6P NXfZNWtLW0GQR1XS
COLO-320-HSR NUjIWmlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrnWWJKSzVyPUOuPVIhdk1? MXfTRW5ITVJ?
RCC10RGB MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDOTWM2OD1|LkmzJI5O M3rHVnNCVkeHUh?=
HD-MY-Z NYn6WXd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHYe4FpUUN3ME2zMlk{KG6P MljsV2FPT0WU
NCI-H2141 NGnzbW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HTUGlEPTB;ND6wOUBvVQ>? M4O2UHNCVkeHUh?=
K-562 NXX5N3p4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PsZWlEPTB;ND6xNkBvVQ>? NHfkPWpUSU6JRWK=
NCI-H1648 MoDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTRwMUOgcm0> NEjrUFhUSU6JRWK=
OMC-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVm1SJFiUUN3ME20MlE5KG6P MkCxV2FPT0WU
LB647-SCLC MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\PTWM2OD12LkKyJI5O MWHTRW5ITVJ?
TE-12 M1LS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjjNVI3UUN3ME20MlI2KG6P NFLmcmZUSU6JRWK=
NOMO-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnuN2lLUUN3ME20MlM{KG6P M3\zRnNCVkeHUh?=
Raji MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHvSYNKSzVyPUSuOFYhdk1? NHHhXlFUSU6JRWK=
NALM-6 NWi3VG4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFO0PJBKSzVyPUSuOFkhdk1? MnzQV2FPT0WU
HL-60 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\GNmlEPTB;ND62O{BvVQ>? NHT1RnVUSU6JRWK=
IST-SL1 M13WeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3u0b2lEPTB;ND62PEBvVQ>? MXrTRW5ITVJ?
MHH-PREB-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnnUZRKSzVyPUSuPFYhdk1? MYTTRW5ITVJ?
MHH-NB-11 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7wd41KSzVyPUSuPVEhdk1? MYPTRW5ITVJ?
JiyoyeP-2003 NVX0bXhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrHfoJKSzVyPUWgcm0> NYPZdGxjW0GQR1XS
SBC-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jhW2lEPTB;NT6wNUBvVQ>? MWrTRW5ITVJ?
CHP-126 MmraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HGemlEPTB;NT6wOkBvVQ>? NYTETmVQW0GQR1XS
LU-139 MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPPdnFKSzVyPUWuNVMhdk1? NHPES3FUSU6JRWK=
NCI-SNU-5 MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHOyTodKSzVyPUWuNVchdk1? MoPCV2FPT0WU
SW962 NXK0OJkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrwSVlKSzVyPUWuNlEhdk1? M1zhR3NCVkeHUh?=
EW-1 Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NECyV3FKSzVyPUWuN|Ehdk1? NIrVOGlUSU6JRWK=
NCI-H1417 NEL2dY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nme2lEPTB;NT61NUBvVQ>? M2e4fHNCVkeHUh?=
LU-65 NHzSSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzYbHNGUUN3ME21Mlg1KG6P NIjPV5lUSU6JRWK=
D-502MG NGLlToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVG1clE2UUN3ME22MlM4KG6P MkXnV2FPT0WU
BC-3 MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnCW5RNUUN3ME22MlYyKG6P NWi2eJdiW0GQR1XS
GDM-1 NGC0clBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTZwN{egcm0> NVrOeXZRW0GQR1XS
NCI-H2196 M1zyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnYbpN6UUN3ME22Mlghdk1? MVLTRW5ITVJ?
NB1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHQTWM2OD14Lki4JI5O M4PGO3NCVkeHUh?=
NCI-H345 MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTdwMjDuUS=> NEPRRYJUSU6JRWK=
SU-DHL-1 NVv6NHpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3UTWM2OD15LkK0JI5O NWLRdHVuW0GQR1XS
JVM-2 M1i1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\TTWM2OD15LkK4JI5O MkjDV2FPT0WU
LU-134-A MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnsUlVKSzVyPUeuN|khdk1? NVf4e3RwW0GQR1XS
NCI-H1694 NXnQNHNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUT4cnFPUUN3ME23MlU5KG6P MYPTRW5ITVJ?
NCI-SNU-16 NWX3U4FTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTdwNkWgcm0> MnfUV2FPT0WU
L-363 M2[1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LnbWlEPTB;Nz63JI5O NILMPGlUSU6JRWK=
KG-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonDTWM2OD15Lkm0JI5O MlX0V2FPT0WU
MN-60 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TLSGlEPTB;OD6xOEBvVQ>? NUf3PXQzW0GQR1XS
NB6 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\tOplKSzVyPUiuOFghdk1? NXLTeFhWW0GQR1XS
MLMA Ml\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRThwOEWgcm0> NH31ZWVUSU6JRWK=
ATN-1 M3iySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjzW5I{UUN3ME24Mlg6KG6P MkLnV2FPT0WU
SK-NEP-1 M3yxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnf6TWM2OD17LkCxJI5O M2PHOHNCVkeHUh?=
DMS-114 MnSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTlwNkKgcm0> NVOxeG85W0GQR1XS
CTB-1 NYDxSmE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXO2SoRJUUN3ME25MlY4KG6P NIHLRY5USU6JRWK=
NCI-H2081 NXjM[nZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTRTWM2OD1zMD6wPUBvVQ>? NUjkZnZTW0GQR1XS
ES5 NFHFSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTFyLkO4JI5O MXPTRW5ITVJ?
HCC1599 MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTFzLkmxJI5O M1;ycXNCVkeHUh?=
NCI-H23 NF3I[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[0TWM2OD1zMj6xNkBvVQ>? NWOzWFFWW0GQR1XS
NCI-H1581 NWO5NYZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlOzTWM2OD1zMj6yPEBvVQ>? MX3TRW5ITVJ?
JVM-3 NWrNbnZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\tTWM2OD1zMj65PUBvVQ>? M2fhSnNCVkeHUh?=
NCI-SNU-1 NVi2[4MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnCZWZJUUN3ME2xN{4yQSCwTR?= MYPTRW5ITVJ?
NB7 NYLEe4NRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofETWM2OD1zNT65NkBvVQ>? M1fsXHNCVkeHUh?=
JAR NUjiN|VuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XIZ2lEPTB;MU[uNVMhdk1? NVzucYVHW0GQR1XS
TGW M2r5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF4LkS4JI5O M4X2PXNCVkeHUh?=
U-87-MG NYryeXhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfhPGVHUUN3ME2xOk44PiCwTR?= NXvvSYhqW0GQR1XS
NCI-H1436 NVXQRpp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDod2RKSzVyPUG3MlAyKG6P NWXkXFRFW0GQR1XS
GOTO MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTF5LkC2JI5O NYfp[phQW0GQR1XS
COLO-800 MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHpc5hKSzVyPUG3MlY1KG6P MUHTRW5ITVJ?
MFM-223 NYrXR4F[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7me5pHUUN3ME2xO{46OSCwTR?= MX7TRW5ITVJ?
EW-18 MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTF5Lkm2JI5O NIrMRlVUSU6JRWK=
NB14 M4rVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;xUZduUUN3ME2xO{46QCCwTR?= Mn[yV2FPT0WU
EB2 M1z5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LMdmlEPTB;MUiuNFghdk1? M3vne3NCVkeHUh?=
EoL-1- MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33JemlEPTB;MUiuN|Ehdk1? MYLTRW5ITVJ?
NCCIT M4WzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTF6LkO2JI5O NWD0dWxiW0GQR1XS
DG-75 NFrx[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWGxVZFSUUN3ME2xPE43OSCwTR?= NHvo[GZUSU6JRWK=
HCC2218 M3\uU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jaXWlEPTB;MUmuOUBvVQ>? MlnlV2FPT0WU
TE-6 NVexOYJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4T0[GlEPTB;MkCuNFghdk1? NH25SJlUSU6JRWK=
SF539 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrGOmlKSzVyPUKwMlY4KG6P Mn3CV2FPT0WU
NCI-H446 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJzLkG4JI5O Mln0V2FPT0WU
IST-MES1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGewS3ZKSzVyPUKyMlc4KG6P NWTIe25jW0GQR1XS
NCI-H82 Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPsTWM2OD1{Mz6wNkBvVQ>? MmjmV2FPT0WU
HCC2157 MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTJ|LkGzJI5O MV7TRW5ITVJ?
EW-12 MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHOUm9oUUN3ME2yN{4yPyCwTR?= Mn3wV2FPT0WU
SIMA MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;xUpdKSzVyPUKzMlM5KG6P NHu0SlRUSU6JRWK=
DOHH-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJ|LkS1JI5O NVLUbXhDW0GQR1XS
IM-9 NIq2O25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzUV|BqUUN3ME2yN{42PCCwTR?= M{PDXHNCVkeHUh?=
EC-GI-10 M33hU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUT4[3o5UUN3ME2yOE4zOyCwTR?= NI\BV4JUSU6JRWK=
HDLM-2 MmnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnVcHJKSzVyPUK0MlU1KG6P MlvJV2FPT0WU
LS-1034 MlPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33WWWlEPTB;MkWuO|Uhdk1? M1njfHNCVkeHUh?=
REH NFjQWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEn1ZmdKSzVyPUK2MlQyKG6P M2ja[3NCVkeHUh?=
LU-165 MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HJUGlEPTB;Mk[uO|Ihdk1? NGfzbINUSU6JRWK=
NH-12 NVfwU|czT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTtemxKSzVyPUK3MlY4KG6P MUXTRW5ITVJ?
WSU-NHL Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LqfGlEPTB;MkiuN|khdk1? Mn31V2FPT0WU
ECC4 Moj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfVTWM2OD1{OD63PUBvVQ>? NUXqTGljW0GQR1XS
OCI-AML2 M4rF[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTJ7Lk[5JI5O NInkbGxUSU6JRWK=
EW-3 MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTNyLkW5JI5O NHrSUpFUSU6JRWK=
NCI-H526 NW\5RYRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2O4bWlEPTB;M{KuOVQhdk1? NXXINnFNW0GQR1XS
NCI-H719 NWf5e5JTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfwWpdKSzVyPUO0MlMyKG6P NHrIeG5USU6JRWK=
KARPAS-422 M3[0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[4TWM2OD1|NT6wOEBvVQ>? NYK2UYx6W0GQR1XS
SK-MEL-1 NIXyfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTN3LkG3JI5O MXTTRW5ITVJ?
ES3 NH76[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;5TWM2OD1|NT6xPUBvVQ>? NITJc3NUSU6JRWK=
UACC-812 MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLNTWM2OD1|NT60OEBvVQ>? MlzsV2FPT0WU
C8166 NU\NUW46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\XV2lEPTB;M{WuO{BvVQ>? Mn[yV2FPT0WU
MDA-MB-134-VI NXTMc5RrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjvNlFKSzVyPUO1Mlg4KG6P NFfuW3VUSU6JRWK=
D-283MED M{DmR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTN5Lke5JI5O M2DBfnNCVkeHUh?=
SHP-77 NXq2UZFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\5UGlEPTB;M{iuNFMhdk1? NGXISGNUSU6JRWK=
NCI-H2227 NIqzZm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTRyLkS5JI5O M17hZXNCVkeHUh?=
SKM-1 MoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLjPYs6UUN3ME20Nk43OyCwTR?= NFP2RotUSU6JRWK=
L-428 NYHYR4k3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTR|Lki2JI5O NWroVG1QW0GQR1XS
RPMI-6666 M3z2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HmSmlEPTB;NEWuPFkhdk1? MlHIV2FPT0WU
NCI-H716 M1;TNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTR6LkixJI5O MYLTRW5ITVJ?
DMS-79 NWK0cYVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYiyOXl2UUN3ME21NE44OSCwTR?= MVLTRW5ITVJ?
RS4-11 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTVyLki4JI5O MoXqV2FPT0WU
NCI-H720 NFXwd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFf6[|RKSzVyPUWxMlEyKG6P MXzTRW5ITVJ?
MC-CAR M3T6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTVzLkWyJI5O MkTJV2FPT0WU
TALL-1 NUjU[4xxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHvTWM2OD13Mz65NUBvVQ>? NXLSVlJzW0GQR1XS
NCI-N87 M3PDeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnsUFNKSzVyPUW0MlE5KG6P MmjEV2FPT0WU
P30-OHK NV3B[GVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXkTWM2OD13ND62NUBvVQ>? MU\TRW5ITVJ?
LP-1 M{LKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\BN4hXUUN3ME22NU4zQCCwTR?= NEmxeIVUSU6JRWK=
YT MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHY[Y5JUUN3ME22NU45KG6P M1fpcHNCVkeHUh?=
MRK-nu-1 MnXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\EVXRKSzVyPU[xMlgzKG6P M{PZSXNCVkeHUh?=
BT-474 MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTZ3IH7N M2C1Z3NCVkeHUh?=
NCI-H322M MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFi5Z4RKSzVyPU[2MlEyKG6P MXfTRW5ITVJ?
NCI-H128 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoO5TWM2OD15ND63O{BvVQ>? MW\TRW5ITVJ?
KMS-12-PE NXjNV3VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzFXnBKSzVyPUe2MlI1KG6P MmX4V2FPT0WU
KP-N-YS M1m4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3yTWM2OD15Nj63OEBvVQ>? MorlV2FPT0WU
ALL-PO M3\rd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPj[lZKSzVyPUe3MlY3KG6P MVPTRW5ITVJ?
EW-13 NVX6eIxTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PhfGlEPTB;N{euO|Yhdk1? Mnz3V2FPT0WU
EW-11 NUfKcXA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXjZ49KSzVyPUe4MlUzKG6P MoDuV2FPT0WU
SK-N-FI MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILDR4JKSzVyPUiwMlIhdk1? MYjTRW5ITVJ?
CAL-148 NF;FSXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRThzLki0JI5O NXL1T3JzW0GQR1XS
RL NWHmNZlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4e4WGlEPTB;OE[uNFkhdk1? NWLVRmx5W0GQR1XS
AM-38 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3r2NmlEPTB;OEiuNFghdk1? NXfpdYo5W0GQR1XS
RH-1 NFWwW2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzDTI5zUUN3ME25PU45PSCwTR?= NUfuT5lnW0GQR1XS
NCI-H1770 NXPGOlNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInITJFKSzVyPUGwNk41QSCwTR?= MXTTRW5ITVJ?
SIG-M5 M{nJ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHpZ2FKSzVyPUGwOU4xPiCwTR?= MkDtV2FPT0WU
GR-ST NFPpR4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP6cmhKSzVyPUGxN{4{PCCwTR?= M2rWVXNCVkeHUh?=
ST486 Ml;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fHdWlEPTB;MUG0MlA3KG6P NXuw[pRYW0GQR1XS
NCI-H1650 Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTFzNT6yPUBvVQ>? M3XXTnNCVkeHUh?=
MHH-CALL-2 NWD6PFM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnod2cyUUN3ME2xNVUvPyCwTR?= Mn;6V2FPT0WU
BV-173 MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{K2dGlEPTB;MUKyMlcyKG6P NFS5eXBUSU6JRWK=
MC116 NGHaNVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXjOJZKSzVyPUG0PE45PSCwTR?= NHjPRWFUSU6JRWK=
NCI-H524 NH\4[41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTF3OT6xJI5O M1HOdHNCVkeHUh?=
SCLC-21H NVrLUHFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\XPGlEPTB;MUW5MlQyKG6P NXPqXZJSW0GQR1XS
NCI-H1304 NEjIe|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTF4OT6yNUBvVQ>? M2fUTHNCVkeHUh?=
NCI-H510A MnHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvCTWM2OD1zOEWuN|chdk1? NIS2N3hUSU6JRWK=
NCI-H209 M1:4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1u5[WlEPTB;MUm2MlUzKG6P NWXadWppW0GQR1XS
KM-H2 MmPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTF7Nz6wOUBvVQ>? M3fQVHNCVkeHUh?=
NCI-H1395 NVzWUG86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHoWJBKSzVyPUKxNE4yOyCwTR?= NE\GPGRUSU6JRWK=
NCI-H1155 NH7GbolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnzU|BKSzVyPUKzNE4{OiCwTR?= MXvTRW5ITVJ?
COR-L279 MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXadmdSUUN3ME2yOVIvOTdibl2= NGmyTVhUSU6JRWK=
NCI-H1299 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4q2PGlEPTB;Mk[xMlcyKG6P M2T5ZnNCVkeHUh?=
EW-22 NITR[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPRT3NKSzVyPUK2N{44PSCwTR?= MoHBV2FPT0WU
SK-MEL-2 NXLiWG5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnOwTWM2OD1{OEGuPUBvVQ>? NFL0XGJUSU6JRWK=
KASUMI-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnNdW9lUUN3ME2yPFMvODVibl2= NVe1XGZvW0GQR1XS
NCI-H187 M2jEOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTJ6Nz6wPEBvVQ>? NV3HVIRGW0GQR1XS
NCI-H2171 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\tTWM2OD1{OEiuPVIhdk1? MmPoV2FPT0WU
LNCaP-Clone-FGC NWL4b3V2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjJe4VKSzVyPUK5OU4zPiCwTR?= NGnp[4VUSU6JRWK=
NCI-H1522 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzCc4ppUUN3ME2zNFcvODVibl2= MkD2V2FPT0WU
SCH NVXTe|dST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjmWm5GUUN3ME2zNlIvOjJibl2= MkXCV2FPT0WU
THP-1 MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnPcYxkUUN3ME2zNlIvPiCwTR?= MX3TRW5ITVJ?
SNU-C1 MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTN4Mj6wPUBvVQ>? MVXTRW5ITVJ?
CA46 NFSzSnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnNPIx4UUN3ME2zO|MvPjNibl2= NWHZPIJiW0GQR1XS
NCI-H1963 NEPJcHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jxRWlEPTB;M{i2MlE6KG6P MnfDV2FPT0WU
DEL NVrsfmVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\2TWM2OD1|OUGuNlchdk1? M1jsVXNCVkeHUh?=
TUR NXLkXm8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLqO4dKSzVyPUO5Ok43OSCwTR?= MXnTRW5ITVJ?
NCI-H226 MoC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDIZppKSzVyPUSwN{4zOyCwTR?= MVzTRW5ITVJ?
COLO-668 NH;4boNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfsTWM2OD12MEOuOVchdk1? NF\nTnNUSU6JRWK=
CPC-N NF7aV5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13vdmlEPTB;NECzMlc4KG6P NIPIdoRUSU6JRWK=
NCI-H889 NUTnVI1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7MTWM2OD12NkGuPVIhdk1? MlLqV2FPT0WU
J-RT3-T3-5 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:0fJIxUUN3ME21N|IvPTdibl2= MmroV2FPT0WU
MSTO-211H MljoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrzUWpNUUN3ME21O|QvOjZibl2= NVjOUIFPW0GQR1XS
SCC-15 M4\pWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTZ4Nz60O{BvVQ>? NFHTTVBUSU6JRWK=
SUP-T1 M1vuS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPxZ2tKSzVyPU[4Ok4xPCCwTR?= NV;hSFJDW0GQR1XS
DMS-153 MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjWZnVKSzVyPUe0Ok45OyCwTR?= Mn3aV2FPT0WU
MS-1 NUftSph{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zoe2lEPTB;N{W5MlQzKG6P M1vYWXNCVkeHUh?=
TC-YIK NWXCUHZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\zTWM2OD15OEGuNFEhdk1? NXPsRoNzW0GQR1XS
RPMI-8866 NV3jOXc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTFyME[uNlgh|ryP Ml[0V2FPT0WU
KY821 MlHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfZUIZTUUN3ME2xNFM3NjB2IN88US=> MUfTRW5ITVJ?
P31-FUJ MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fYTWlEPTB;MUGxNk44PSEQvF2= NYTLZlh{W0GQR1XS
COLO-824 MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17kUGlEPTB;MUK2NU44QCEQvF2= MYfTRW5ITVJ?
U-698-M NYPuU3k2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PPR2lEPTB;MkK2Nk4yPSEQvF2= M1W5eXNCVkeHUh?=
TE-441-T NITV[HFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULxcFlTUUN3ME2yOVIyNjdizszN MXzTRW5ITVJ?
IMR-5 NVy5enpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIeyTnZKSzVyPUO0NFkvPjJizszN NVXwXJh2W0GQR1XS
NCI-H1838 NX3lUYpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTLfXc1UUN3ME20NVg3NjN{IN88US=> MXzTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
phospho-PERK / ATF-4; 

PubMed: 15509775     


UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against phospho-PERK, ATF-4. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. 

GRP-78 / GADD-34; 

PubMed: 15509775     


UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against GRP-78, and GADD-34. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. 

pro-caspase-12 / pro-caspase-3; 

PubMed: 15509775     


MEFs were treated with PS-341 for the indicated time periods, and the whole-cell extracts were prepared. Fifty-microgram aliquots of proteins were probed with polyclonal antibodies against caspase 12 and caspase 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin. 

pro-caspase-9; 

PubMed: 15509775     


UMSCC-23 cells were pretreated with or without Tiron for 30 min and then treated with PS-341 for the indicated time periods. The whole-cell proteins were probed with polyclonal antibodies against caspases 9 and 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin.

p-IκBα / IκBα; 

PubMed: 20335171     


PS-341 induces IκBα degradation in human lung cancer cells. The given cells lines were treated with the indicated concentrations of PS-341 for 8 h (C). After treatment, the cells were then subjected to preparation of whole-cell protein lysates and subsequent Western blot analysis. 

COX-2 / cIAP2; 

PubMed: 24085292     


NCI-H157 cells were incubated with PS-341 (50 nM) or MG132 (20 μM) for the indicated times.  Total cellular extracts were subjected to Western blot analysis for COX-2, cIAP2 and actin. 

15509775 20335171 24085292
Immunofluorescence
Vimentin; 

PubMed: 19010849     


ES-2 ovarian cancer cells were incubated with 5nM PS-341, 10 μM NK84 or the combination of both for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective). 

Ubiquitin; 

PubMed: 19010849     


IOSE-29 cells were incubated with 20nM PS-341 for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective). 

19010849
Growth inhibition assay
Cell viability ; 

PubMed: 20571067     


A, TSA enhanced the cell death induced by PS-341 in UMSCC1 cells. Cell viability was determined by the trypan blue exclusion assay. The assays were performed with triplicate samples, and the results are representative of three independent experiments (**P < 0.01). Error bars depict standard deviation. B, C and D, TSA enhanced PS-341-induced cell death in UMSCC23 (B), UMSCC9 (C), and FaDu (D). **P < 0.01.

20571067
ELISA
IL-8; 

PubMed: 24085292     


NCI-H157 cells were treated with PS-341 (10–100 nm) or TNF-α (10 ng/ml) as a positive control for 24 h. IL-8 concentrations in media were determined by ELISA. Data represent the mean ± S.D. of triplicates. **, p < 0.05 versus control cells. Results are representative of three separate experiments.

24085292
In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]

+ Expand

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]

+ Expand
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4

CAS No. 179324-69-7
Storage powder
in solvent
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03829020 Not yet recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma Mayo Clinic|National Cancer Institute (NCI) March 1 2019 Phase 1
NCT03617484 Recruiting Mantle Cell Lymphoma University of Michigan Rogel Cancer Center March 2019 Phase 2
NCT03617484 Recruiting Mantle Cell Lymphoma University of Michigan Rogel Cancer Center March 2019 Phase 2
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03829020 Not yet recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma Mayo Clinic|National Cancer Institute (NCI) March 1 2019 Phase 1
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • Answer:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products3

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID